Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Johnson and Johnson
Fuji
Boehringer Ingelheim
Mallinckrodt

Generated: June 19, 2019

DrugPatentWatch Database Preview

Valeant Pharms Company Profile

« Back to Dashboard

Summary for Valeant Pharms
International Patents:136
US Patents:30
Tradenames:39
Ingredients:36
NDAs:46

Drugs and US Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No 7,572,935 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,569,610 ➤ Sign Up ➤ Sign Up
Valeant Pharms Intl CUPRIMINE penicillamine CAPSULE;ORAL 019853-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No 7,241,805 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,585,897 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-001 Dec 24, 1985 AB RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Valeant Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms LIBRAX chlordiazepoxide hydrochloride; clidinium bromide CAPSULE;ORAL 012750-001 Approved Prior to Jan 1, 1982 4,316,897 ➤ Sign Up
Valeant Pharms North CARAC fluorouracil CREAM;TOPICAL 020985-001 Oct 27, 2000 4,690,825 ➤ Sign Up
Valeant Pharms North RETIN-A tretinoin CREAM;TOPICAL 017340-001 Approved Prior to Jan 1, 1982 3,906,108 ➤ Sign Up
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 4,801,576 ➤ Sign Up
Valeant Pharms Intl TIMOPTIC timolol maleate SOLUTION/DROPS;OPHTHALMIC 018086-002 Approved Prior to Jan 1, 1982 3,655,663 ➤ Sign Up
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-005 Jul 26, 1988 4,374,829*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 2007-03-28
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 2013-03-11
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 2007-01-08
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2007-09-25
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 2012-04-03
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24

Supplementary Protection Certificates for Valeant Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 CA 2017 00062 Denmark ➤ Sign Up PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
0957929 SZ 20/2006 Austria ➤ Sign Up PRODUCT NAME: PEGAPTANIB UND SALZE DAVON
0957929 20/2006 Austria ➤ Sign Up PRODUCT NAME: PEGAPTANIB UND SALZE DAVON; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
2316456 C201730057 Spain ➤ Sign Up PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
0656775 CR 2000 00018 Denmark ➤ Sign Up PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
2316456 2017C/064 Belgium ➤ Sign Up PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Harvard Business School
Queensland Health
Medtronic
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.